| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
154,660,000 |
| Market
Cap: |
9.11(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.0569 - $1.27 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Adaptimmune Therapeutics is a biopharmaceutical company focused on developing T-cell therapies for solid tumors. Co.'s proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors against those targets, and produce therapeutic candidates (SPEAR T-cells) for administration to patients. Co. has clinical trials on its ADP-A2M4, ADP-A2M4CD8, each targeting the MAGE-A4 antigen, and ADP-A2AFP SPEAR T-cells targeting the alpha fetoprotein (AFP) cancer antigen in solid tumor types including non-small cell lung cancer, head and neck cancer, ovarian, urothelial, melanoma, and hepatocellular.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
83,552,538 |
83,552,538 |
83,733,730 |
83,924,060 |
| Total Sell Value |
$7,119,408 |
$7,119,408 |
$7,224,658 |
$7,371,857 |
| Total People Sold |
2 |
2 |
7 |
7 |
| Total Sell Transactions |
5 |
5 |
18 |
35 |
| End Date |
2025-06-01 |
2025-02-28 |
2024-08-30 |
2023-08-31 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bertrand William C Jr |
Chief Operating Officer |
• – – |
2025-08-28 |
4 |
S |
$0.01 |
$2,091 |
D/D |
(207,000) |
986,352 |
|
- |
|
| Behbahani Ali |
|
– • – |
2025-08-18 |
4 |
S |
$0.01 |
$176,062 |
I/I |
(14,671,794) |
0 |
|
2% |
|
| Behbahani Ali |
|
– • – |
2025-08-15 |
4 |
S |
$0.01 |
$53,110 |
I/I |
(4,828,206) |
14,671,794 |
|
-16% |
|
| Ecor1 Capital, Llc |
10% Owner |
– – • |
2025-07-30 |
4 |
S |
$0.10 |
$2,800,944 |
I/I |
(27,433,338) |
100,371,882 |
|
31% |
|
| Ecor1 Capital, Llc |
10% Owner |
– – • |
2025-07-29 |
4 |
S |
$0.10 |
$271,971 |
I/I |
(2,687,460) |
127,805,220 |
|
34% |
|
| Ecor1 Capital, Llc |
10% Owner |
– – • |
2025-07-28 |
4 |
S |
$0.11 |
$3,817,321 |
I/I |
(33,931,740) |
130,492,680 |
|
31% |
|
| Norry Elliot |
Chief Medical Officer |
• – – |
2025-01-17 |
4 |
S |
$0.58 |
$3,243 |
D/D |
(5,584) |
7,510 |
|
53% |
|
| Rawcliffe Adrian |
Chief Executive Officer |
• • – |
2025-01-17 |
4 |
S |
$0.58 |
$17,773 |
D/D |
(30,601) |
44,327 |
|
53% |
|
| Lunger John |
Chief Patient Supply Officer |
• – – |
2025-01-17 |
4 |
S |
$0.58 |
$3,243 |
D/D |
(5,584) |
7,510 |
|
53% |
|
| Bertrand William C Jr |
Chief Operating Officer |
• – – |
2025-01-17 |
4 |
S |
$0.58 |
$3,243 |
D/D |
(5,584) |
7,510 |
|
53% |
|
| Norry Elliot |
Chief Medical Officer |
• – – |
2025-01-15 |
4 |
S |
$0.57 |
$5,635 |
D/D |
(9,803) |
13,756 |
|
54% |
|
| Bertrand William C Jr |
Chief Operating Officer |
• – – |
2025-01-15 |
4 |
S |
$0.57 |
$5,635 |
D/D |
(9,803) |
13,756 |
|
54% |
|
| Rawcliffe Adrian |
Chief Executive Officer |
• • – |
2025-01-15 |
4 |
S |
$0.57 |
$16,724 |
D/D |
(29,096) |
41,582 |
|
54% |
|
| Piccina Cintia |
Chief Commercial Officer |
• – – |
2025-01-15 |
4 |
S |
$0.57 |
$7,467 |
D/D |
(12,991) |
18,421 |
|
54% |
|
| Lunger John |
Chief Patient Supply Officer |
• – – |
2025-01-15 |
4 |
S |
$0.57 |
$5,635 |
D/D |
(9,803) |
13,756 |
|
54% |
|
| Norry Elliot |
Chief Medical Officer |
• – – |
2025-01-13 |
4 |
S |
$0.59 |
$7,285 |
D/D |
(12,392) |
11,516 |
|
54% |
|
| Bertrand William C Jr |
Chief Operating Officer |
• – – |
2025-01-13 |
4 |
S |
$0.59 |
$5,726 |
D/D |
(9,739) |
7,623 |
|
54% |
|
| Rawcliffe Adrian |
Chief Executive Officer |
• • – |
2025-01-13 |
4 |
S |
$0.59 |
$17,915 |
D/D |
(30,473) |
25,711 |
|
54% |
|
| Lunger John |
Chief Patient Supply Officer |
• – – |
2025-01-13 |
4 |
S |
$0.59 |
$5,726 |
D/D |
(9,739) |
7,623 |
|
54% |
|
| Piccina Cintia |
Chief Commercial Officer |
• – – |
2024-06-18 |
4 |
S |
$0.93 |
$22,814 |
D/D |
(24,531) |
38,293 |
|
16% |
|
| Ecor1 Capital, Llc |
10% Owner |
– – • |
2024-03-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
164,424,420 |
|
-33% |
|
| Norry Elliot |
Chief Medical Officer |
• – – |
2024-01-17 |
4 |
S |
$0.67 |
$12,300 |
D/D |
(18,276) |
19,257 |
|
-43% |
|
| Lunger John |
Chief Patient Supply Officer |
• – – |
2024-01-17 |
4 |
S |
$0.67 |
$12,191 |
D/D |
(18,114) |
19,015 |
|
-43% |
|
| Bertrand William C Jr |
Chief Operating Officer |
• – – |
2024-01-17 |
4 |
S |
$0.67 |
$12,725 |
D/D |
(18,908) |
20,201 |
|
-43% |
|
| Rawcliffe Adrian |
Chief Executive Officer |
• • – |
2024-01-17 |
4 |
S |
$0.67 |
$20,244 |
D/D |
(30,080) |
44,848 |
|
-43% |
|
254 Records found
|
|
Page 1 of 11 |
|
|
0.01 (14.51%) 
